Camber Launches Chlorzoxazone Tablets, USP

Piscataway, NJ, April 29, 2025 –Camber Pharmaceuticals is excited to announce the addition of Chlorzoxazone Tablets, USP.
Chlorzoxazone Tablets, USP are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.
Chlorzoxazone 250 mg Tablets, USP are available in 60 count bottles.
To find out more information on Chlorzoxazone Tablets, USP, please visit: www.camberpharma.com/chlorzoxazone
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dose manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers and improving quality of life through cost-effective medications.
Recent articles
- Camber Launches Phenylephrine Hydrochloride Injection, USP
- Camber Launches Chlorzoxazone Tablets, USP
- Camber Launches 13 New Generic Products in Q1 2025, Sets Ambitious Pace for the Year
- Camber Launches Lurasidone Hydrochloride Tablets
- Camber Launches Mycophenolate Mofetil Capsules
- Camber Launches Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution